UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): July 7, 2015

 

 

JAGUAR ANIMAL HEALTH, INC.

(Exact name of registrant as specified in its charter)

 

 

 

Registrant’s telephone number, including area code: (415) 371-8300

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

o      Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o      Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

o      Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

o      Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

 

Contingent Options Granted to Certain Officer

 

On July 7, 2015, the board of directors of Jaguar Animal Health, Inc., a Delaware corporation (the “Company”), upon recommendation of its Compensation Committee, authorized the grant of an aggregate of 113,212 options to purchase shares of the Company’s common stock to Ms. Lisa A. Conte, the Company’s President and Chief Executive Officer, which grant is contingent upon receiving necessary stockholder approval of the increase in the number of shares of the Company’s common stock authorized for issuance under the Jaguar Animal Health 2014 Stock Incentive Plan (the “Contingent Options”).   The Contingent Options will vest monthly over three (3) years such that they are vested in full on the third year anniversary of the grant authorization date, have an exercise price of $4.84 per share, and expire ten (10) years from the grant authorization date.

 

2

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

	JAGUAR ANIMAL HEALTH, INC.
	By:	/s/ John A. Kallassy
		Name:	John A. Kallassy
		Title:	Executive Vice President, Chief Financial Officer, Chief Operating Officer and Treasurer

 

 

Date: July 10, 2015

 

3